ArticleBMC cancer2025
Copper's new role in cancer: how cuproptosis-related genes could revolutionize glioma treatment.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Glutathione reductase deficiency potentiates the immunogenicity of ferroptosis and cuproptosis via amplified reactive oxygen species accumulation and cGAS-STING pathway activation.Journal of hematology & oncology · 2026Article
- Copper homeostasis and cuproptosis in cancer: mitochondrial metabolic dependency and nanomedicine-based therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026Review
- A novel cuproptosis-related prognostic gene signature is identified by machine learning and integrative analyses in gliomas.Molecular and cellular biochemistry · 2026Article
- Copper Transporter 1‑Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors.ACS pharmacology & translational science · 2026Article
- Role of cuproptosis in digestive system tumors (Review).International journal of molecular medicine · 2026Review
- Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".Oncology research · 2026Review
- Multiomics Characterization of GCSH + Macrophages Reveals Therapeutic Vulnerabilities and Immune-Metabolic Crosstalk in Triple-Negative Breast Cancer.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesCuproptosis, a novel form of regulatory cell death, was investigated in this study for its effects on cuproptosis-associated proteins during gliomas development, offering novel insights into the mechanism of copper ion-based antitumor drugs.
methodsIn the present study, bioinformatics and cellular experiments were employed to investigate cuproptosis-related genes (CRGs) in glioma, with a specific focus on SLC31A1.
resultsThe study findings indicated that many CRGs (SLC31A1, FDX1, DLST, LIPT1, LIPT2, DLD, NFE2L2, ATP7A, DLAT, GCSH, and ATP7B) were differentially expressed between glioma and non-tumor groups. These genes potentially influence glioma initiation and progression by modulating associated signaling pathways, including those involved in cell cycle regulation, inflammatory responses, and the tumor microenvironment. Survival curve analysis and Cox proportional hazard regression model demonstrated that individuals classified as high-risk exhibited poorer prognosis, suggesting that CRGs possess prognostic capabilities. The assessment of tumor mutational burden indicated that CRGs could serve as biomarkers for predicting the efficacy of immunotherapy in glioma. Further functional analysis of SLC31A1 showed that its elevation was associated with increased glioma cell malignancy, promoting proliferation and migration. Additionally, treatment with the mitotic inhibitor MP-HJ-1b markedly suppressed SLC31A1 expression, consequently inhibiting glioma cell proliferation and migration.
conclusionsExtensive data analysis indicated that CRGs hold promise as both prognostic markers and potential therapeutic targets for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.